U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 2 Constipation, CTCAE

MedGen UID:
282062
•Concept ID:
C1559283
•
Finding

Definition

Persistent symptoms with regular use of laxatives or enemas; limiting instrumental ADL [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 2 Constipation, CTCAE

Recent clinical studies

Etiology

A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Chang C, Li X, Cheng K, Cai Z, Xiong J, Lv W, Li R, Zhang P, Cao D
Oncologist 2023 Jul 5;28(7):e575-e584. doi: 10.1093/oncolo/oyac146. PMID: 35930304Free PMC Article
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A
J Headache Pain 2022 May 11;23(1):55. doi: 10.1186/s10194-022-01426-8. PMID: 35538414Free PMC Article
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer.
Rezniczek GA, Giger-Pabst U, Thaher O, Tempfer CB
BMC Cancer 2020 Nov 19;20(1):1122. doi: 10.1186/s12885-020-07627-1. PMID: 33213407Free PMC Article
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ
Prostate 2020 Jan;80(1):99-108. Epub 2019 Nov 19 doi: 10.1002/pros.23922. PMID: 31742767
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S
Acta Oncol 2019 Jun;58(6):916-925. Epub 2019 Mar 18 doi: 10.1080/0284186X.2019.1581373. PMID: 30882264

Diagnosis

Investigating the safety and feasibility of osteopathic medicine in the pediatric oncology outpatient setting.
Belsky JA, Stanek JR, Rose MJ
J Osteopath Med 2022 Apr 15;122(8):423-429. doi: 10.1515/jom-2021-0246. PMID: 35421288
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ
Prostate 2020 Jan;80(1):99-108. Epub 2019 Nov 19 doi: 10.1002/pros.23922. PMID: 31742767
Evaluation of interobserver and interscale agreement in assessing late bowel toxicity after pelvic radiation in patients with carcinoma of the cervix.
Chinnachamy AN, Chopra S, Krishnatry R, Kannan S, Thomas B, Mahantshetty U, Engineer R, Shrivastava SK
Jpn J Clin Oncol 2013 May;43(5):508-14. Epub 2013 Mar 20 doi: 10.1093/jjco/hyt028. PMID: 23515269
Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).
Yamada K, Tanabe H, Imai M, Jobo T, Kudo K, Fujiwara H, Nagata C, Furuya K, Suzuki M, Ochiai K, Tanaka T, Yasuda M
J Obstet Gynaecol Res 2013 Jan;39(1):311-6. Epub 2012 May 28 doi: 10.1111/j.1447-0756.2012.01890.x. PMID: 22639962

Therapy

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Leary A, Oaknin A, Trigo JM, Moreno V, Delord JP, Boni V, Braña I, Fernández C, Kahatt C, Nieto A, Cullell-Young M, Zeaiter A, Subbiah V
Eur J Cancer 2023 Oct;192:113259. Epub 2023 Jul 28 doi: 10.1016/j.ejca.2023.113259. PMID: 37634282
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A
J Headache Pain 2022 May 11;23(1):55. doi: 10.1186/s10194-022-01426-8. PMID: 35538414Free PMC Article
Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer.
Lim TL, Pietrofesa RA, Arguiri E, Koumenis C, Feigenberg S, Simone CB 2nd, Rengan R, Cengel K, Levin WP, Christofidou-Solomidou M, Berman AT
J Altern Complement Med 2021 Oct;27(10):824-831. Epub 2021 Jun 23 doi: 10.1089/acm.2020.0542. PMID: 34161146
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ
Prostate 2020 Jan;80(1):99-108. Epub 2019 Nov 19 doi: 10.1002/pros.23922. PMID: 31742767
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S
Acta Oncol 2019 Jun;58(6):916-925. Epub 2019 Mar 18 doi: 10.1080/0284186X.2019.1581373. PMID: 30882264

Prognosis

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A
J Headache Pain 2022 May 11;23(1):55. doi: 10.1186/s10194-022-01426-8. PMID: 35538414Free PMC Article
Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer.
Lim TL, Pietrofesa RA, Arguiri E, Koumenis C, Feigenberg S, Simone CB 2nd, Rengan R, Cengel K, Levin WP, Christofidou-Solomidou M, Berman AT
J Altern Complement Med 2021 Oct;27(10):824-831. Epub 2021 Jun 23 doi: 10.1089/acm.2020.0542. PMID: 34161146
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ
Prostate 2020 Jan;80(1):99-108. Epub 2019 Nov 19 doi: 10.1002/pros.23922. PMID: 31742767
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S
Acta Oncol 2019 Jun;58(6):916-925. Epub 2019 Mar 18 doi: 10.1080/0284186X.2019.1581373. PMID: 30882264

Clinical prediction guides

A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Chang C, Li X, Cheng K, Cai Z, Xiong J, Lv W, Li R, Zhang P, Cao D
Oncologist 2023 Jul 5;28(7):e575-e584. doi: 10.1093/oncolo/oyac146. PMID: 35930304Free PMC Article
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A
J Headache Pain 2022 May 11;23(1):55. doi: 10.1186/s10194-022-01426-8. PMID: 35538414Free PMC Article
Investigating the safety and feasibility of osteopathic medicine in the pediatric oncology outpatient setting.
Belsky JA, Stanek JR, Rose MJ
J Osteopath Med 2022 Apr 15;122(8):423-429. doi: 10.1515/jom-2021-0246. PMID: 35421288
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S
Acta Oncol 2019 Jun;58(6):916-925. Epub 2019 Mar 18 doi: 10.1080/0284186X.2019.1581373. PMID: 30882264
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF
Clin Cancer Res 2018 May 15;24(10):2285-2293. Epub 2018 Mar 2 doi: 10.1158/1078-0432.CCR-17-3055. PMID: 29500276Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...